ArticleJournal of the American Society of Nephrology : JASN2012
APOL1 risk variants predict histopathology and progression to ESRD in HIV-related kidney disease.
Article in Journal of the American Society of Nephrology : JASN, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 3 syntheses or guidelines pooled it, 120 citations in OpenAlex.
- Apolipoprotein L1 gene variants and kidney disease in patients with HIV: a systematic review and meta-analysis.Journal of nephrology · 2023Pooled it
- An African perspective on the genetic risk of chronic kidney disease: a systematic review.BMC medical genetics · 2018Pooled it
- Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.Kidney international · 2018Guideline
- Article
- Review
- Cytochrome P450 3A gene family and medication in childhood nephrotic syndrome: An update.Global medical genetics · 2025Review
- APOL1 Dynamics in Diabetic Kidney Disease and Hypertension.Biomolecules · 2025Review
- Article
- The changing landscape of HIV-associated kidney disease.Nature reviews. Nephrology · 2024Review
- The metabolic effects of APOL1 in humans.Pflugers Archiv : European journal of physiology · 2023Review
- Living kidney donors with HIV: experience and outcomes from a case series by the HOPE in Action Consortium.Lancet regional health. Americas · 2023Article
- Updates on HIV and Kidney Disease.Current HIV/AIDS reports · 2023Review
- Treatment of HIV-Associated Lupus-like Membranous Nephropathy with Tacrolimus: A Case Report and Review of the Literature.Life (Basel, Switzerland) · 2023Article
- The Human Virome and Its Crosslink with Glomerulonephritis and IgA Nephropathy.International journal of molecular sciences · 2023Review
- Genetic Variants ofKidney international reports · 2022Article
- Article
- Similarities and Differences between COVID-19-Associated Nephropathy and HIV-Associated Nephropathy.Kidney diseases (Basel, Switzerland) · 2022Review
- Apoprotein L1 risk variants and kidney transplantation: a protocol for systematic review and meta-analysis.The Pan African medical journal · 2022Article
- APOL1 risk variants in individuals of African genetic ancestry drive endothelial cell defects that exacerbate sepsis.Immunity · 2021Article
- Data-driven modelling of mutational hotspots and in silico predictors in hypertrophic cardiomyopathy.Journal of medical genetics · 2021Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 3 countries.
Funding
Abstract
With earlier institution of antiretroviral therapy, kidney diseases other than HIV-associated nephropathy (HIVAN) predominate in HIV-infected persons. Outcomes for these diseases are typically worse among those infected with HIV, but the reasons for this are not clear. Here, we examined the role of APOL1 risk variants in predicting renal histopathology and progression to ESRD in 98 HIV-infected African Americans with non-HIVAN kidney disease on biopsy. We used survival analysis to determine time to ESRD associated with APOL1 genotype. Among the 29 patients with two APOL1 risk alleles, the majority (76%) had FSGS and 10% had hypertensive nephrosclerosis. In contrast, among the 54 patients with one APOL1 risk allele, 47% had immune-complex GN as the predominant lesion and only 23% had FSGS. Among the 25 patients with no APOL1 risk allele, 40% had immune-complex GN and 12% had FSGS. In 310 person-years of observation, 29 patients progressed to ESRD. In adjusted analyses, individuals with two APOL1 risk alleles had a nearly three-fold higher risk for ESRD compared with those with one or zero risk alleles (P=0.03). In summary, these data demonstrate an association between APOL1 variants and renal outcomes in non-HIVAN kidney disease, suggesting a possible use for APOL1 genotyping to help guide the care of HIV-infected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.